Advanced Wound & Burn Treatment  

Extensive burns and full thickness skin wounds can be devastating to patients, even when treated.

Recent advances in tissue engineering have led to more complex biological skin equivalents that may yield more suitable wound treatment options for patients. These products are generally comprised of a polymer scaffold patch that is seeded with human fibroblasts and cultured in vitro prior to application. Unfortunately, these grafts are also expensive to produce, and similar to allografts, have the same immunological drawbacks.

The cell source used in cellular therapies for wound healing is an important consideration  which has implications for the cost, speed of healing, and outcome of the treatments. Human keratinocytes are perhaps the optimal cell type to employ. However, autologous and allogenic keratinocytes suffer from the same drawbacks as their autologous and allogenic skin graft counterparts; i.e. secondary surgical sites and potential for rejection, respectively. Furthermore, cell therapies have complicated regulatory and financial hurdles to overcome prior to commercialization.

Thus, there is a need for quickly prepared wound healing and tissue engineering products that have high clinical efficiency, and that do not require a living cellular component, but instead retains the bioactivity of a cellular treatment.  Our product candidates satisfy this unmet need.


Features and Benefits of  XCell Biologix™ BioHeal® Hydrogel XG-100 Product Candidate

Features Benefits
Patented technology accelerates wound closure and re-epithelialization and reduces wound contraction Clinical data (animal) shows up to 20% improvement over existing approved amnion based products
Patented technology promotes neo-vascularization and keratinocyte proliferation in vivo; i.e., tissue regeneration Clinical data (animal) shows up to 20%  improvement over existing approved amnion based products
Patented technology Provides optimal cosmetic outcomes
Ease of use Ready-to-use in two minutes, no need for thawing
Ease of storage Off-the-shelf, no need for cryopreservation storage
Ease of handling No suturing
Adequate coverage of wounds No supply issues, unlike allograft skin that is supply limited
Patented process eliminates immune response No immune response, unlike allograft skin which requires immunosuppressive drugs